for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover Interventional Cardiology Clinics
  [SJR: 0.253]   [H-I: 4]   [3 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 2211-7458 - ISSN (Online) 2211-7466
   Published by Elsevier Homepage  [3175 journals]
  • Left Atrial Appendage Occlusion for Stroke Prevention in Patients with
           Atrial Fibrillation
    • Authors: Apostolos Tzikas
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): Apostolos Tzikas


      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/j.iccl.2018.01.002
       
  • A History of Percutaneous Left Atrial Appendage Occlusion with the PLAATO
           Device
    • Authors: Heyder Omran; Apostolos Tzikas; Horst Sievert; Frederike Stock
      Pages: 137 - 142
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): Heyder Omran, Apostolos Tzikas, Horst Sievert, Frederike Stock
      Teaser Percutaneous left atrial appendage occlusion was introduced as an alternative method for prevention of thromboembolism in patients with nonvalvular atrial fibrillation after extensive animal work in 2001. The first device was named Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO) and patented by the company Appriva. The device was invented by Michael Lesh, MD.

      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/j.iccl.2017.12.009
       
  • A History of Left Atrial Appendage Occlusion
    • Authors: David R. Holmes; Robert S. Schwartz; George G. Latus; Robert A. Van Tassel
      Pages: 143 - 150
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): David R. Holmes, Robert S. Schwartz, George G. Latus, Robert A. Van Tassel
      Teaser A new era in antiembolic therapy has been initiated by the growing numbers of device-based therapies. Early concerns surrounding eliminating this enigmatic structure have not proven true. Other benefits are being further evaluated. Many other questions remain, such as whether there is a device-specific outcome effect or whether it is a class effect. Other questions include other devices, what head-to-head studies will show, and the impact of residual leak. Left atrial appendage using the Watchman ablation strategy can reduce cardioembolic stroke, with comparable or fewer adverse effects by device technology than obtained by long-term anticoagulation with its attendant bleeding risks.

      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/j.iccl.2017.12.005
       
  • History of Percutaneous Left Atrial Appendage Occlusion with AMPLATZER
           Devices
    • Authors: Bernhard Meier; Wim Stegink; Apostolos Tzikas
      Pages: 151 - 158
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): Bernhard Meier, Wim Stegink, Apostolos Tzikas
      Teaser AMPLATZER devices preceded WATCHMAN occluder in 2002 for catheter-based left atrial appendage occlusion. The AMPLATZER technique facilitates simultaneous closure of atrial shunts using two devices through one gear. Randomized WATCHMAN follow-up data showed a mortality benefit over warfarin. AMPLATZER data make this likely valid for the strategy. Particularly young people with atrial fibrillation should be offered left atrial appendage occlusion because the risk is confined to the intervention and early postintervention period. Guidelines should be adapted to make this progress in prevention of stroke and bleeding in patients with atrial fibrillation accessible for all, in the sense of a mechanical vaccination.

      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/j.iccl.2017.12.007
       
  • Left Atrial Appendage Occlusion
    • Authors: Matthew J. Price
      Pages: 159 - 168
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): Matthew J. Price
      Teaser Resection of the left atrial appendage (LAA) to prevent recurrent arterial emboli in patients with atrial fibrillation was first suggested more than 60 years ago. Longer-term follow-up from randomized studies of the safety and efficacy of transcatheter LAA occlusion has recently been completed; data from large, observational cohorts are being reported. These recent data provide further insights into procedural safety with current techniques and the ability of LAA closure to reduce thromboembolic stroke compared with warfarin anticoagulation. This review summarizes the latest data regarding transcatheter LAA occlusion, focusing on larger prospective studies and further analyses of seminal clinical trials.

      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/j.iccl.2017.12.002
       
  • Indication, Patient Selection, and Referral Pathways for Left Atrial
           Appendage Closure
    • Authors: Tawseef Dar; Mohit K. Turagam; Bharath Yarlagadda; Mohmad Tantary; Seth H. Sheldon; Dhanunjaya Lakkireddy
      Pages: 169 - 183
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): Tawseef Dar, Mohit K. Turagam, Bharath Yarlagadda, Mohmad Tantary, Seth H. Sheldon, Dhanunjaya Lakkireddy
      Teaser Left atrial appendage closure (LAAC) has emerged as a viable option for stroke prevention, especially in those intolerant of or not suitable for long-term oral anticoagulation therapy. This article describes the clinical characteristics, indications, and a proposed referral system for potential LAAC patients. Patient selection remains a challenge because of the paradox between the available randomized data on this intervention and the actual patient population who may gain maximum benefit. Further investigations comparing different LAAC devices with each other and with novel oral anticoagulants are needed. Also, the optimal antithrombotic regimen post-procedure has yet to be determined.

      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/j.iccl.2017.12.003
       
  • Anatomy and Physiologic Roles of the Left Atrial Appendage
    • Authors: Nicholas Y. Tan; Omar Z. Yasin; Alan Sugrue; Abdallah El Sabbagh; Thomas A. Foley; Samuel J. Asirvatham
      Pages: 185 - 199
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): Nicholas Y. Tan, Omar Z. Yasin, Alan Sugrue, Abdallah El Sabbagh, Thomas A. Foley, Samuel J. Asirvatham
      Teaser The left atrial appendage has been implicated as a major nidus for thrombus formation, particularly in atrial fibrillation. This discovery has prompted substantial interest in the development of left atrial appendage exclusion devices aimed at decreasing systemic thromboembolism risk. Its deceptively simple appearance belies the remarkable complexity that characterizes its anatomy and physiology. We highlight the key anatomic features and variations of the left atrial appendage as well as its relationships with surrounding structures. We also summarize crucial anatomic factors that should be taken into account by the interventional cardiologist when planning for or performing left atrial appendage exclusion procedures.

      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/j.iccl.2017.12.001
       
  • The WATCHMAN Left Atrial Appendage Closure Device
    • Authors: Matthew J. Price
      Pages: 201 - 212
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): Matthew J. Price
      Teaser Randomized clinical trials have demonstrated that left atrial appendage (LAA) closure with the WATCHMAN device provides stroke prevention in nonvalvular atrial fibrillation while significantly reducing morality and major bleeding. Technical and procedural considerations are paramount for the therapeutic success. Maximizing procedural safety is critical. Optimal LAA sealing is required. Improvements in procedural technique and operator training have resulted in a marked reduction in adverse procedural events, which should increase the absolute long-term clinical benefit. This article outlines the key aspects of patient workup and procedural technique for the best possible outcome.

      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/j.iccl.2017.12.010
       
  • The Amplatzer Amulet Device
    • Authors: Nathan Messas; Reda Ibrahim
      Pages: 213 - 218
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): Nathan Messas, Reda Ibrahim
      Teaser Percutaneous left atrial appendage occlusion (LAAO) for stroke prevention in patients with atrial fibrillation has significantly advanced in the past 2 decades. LAAO has emerged as a feasible and safe alternative to oral anticoagulants in patients who are deemed high risk for bleeding or are ineligible to receive anticoagulation. Herein, the authors review the main design features of the AMPLATZER Amulet device and describe step-by-step technical considerations for implantation of this LAAO device.

      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/j.iccl.2017.12.012
       
  • Echocardiographic Imaging for Left Atrial Appendage Occlusion
    • Authors: Dee Dee Wang; Thomas J. Forbes; James C. Lee; Marvin H. Eng
      Pages: 219 - 228
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): Dee Dee Wang, Thomas J. Forbes, James C. Lee, Marvin H. Eng
      Teaser Left atrial appendage occlusion (LAAO) is a rapidly evolving technology. Multi-modality imaging and understanding of left atrial appendage anatomy are sure to advance. Two-dimensional and 3-dimensional transesophageal echocardiography with fluoroscopy are the mainstay for LAAO image-guided therapy. Key to successful LAAO is an understanding of the transseptal puncture, LAAO size selection for the device-specific landing zone, and postdeployment evaluation for leak and complications. With advancements in computed tomography, there may be a greater role for intracardiac echocardiographic imaging in specific types of LAAO anatomy and devices.

      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/j.iccl.2018.01.001
       
  • Incidence, Prevention, and Management of Periprocedural Complications of
           Left Atrial Appendage Occlusion
    • Authors: Jay Thakkar; Dimitra Vasdeki; Apostolos Tzikas; Bernhard Meier; Jacqueline Saw
      Pages: 243 - 252
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): Jay Thakkar, Dimitra Vasdeki, Apostolos Tzikas, Bernhard Meier, Jacqueline Saw
      Teaser Major procedural complications related to left atrial appendage occlusion (LAAO) are relatively infrequent but may be associated with major morbidity and mortality. LAAO operators should be knowledgeable about these potential complications. Prompt recognition and treatment are necessary to avoid rapid deterioration and dire consequences. With stringent guidelines on operator training, competency requirements, and procedural-technical refinements, LAAO can be performed safely with low complication rates. This article focuses on commonly used devices, as well as prevention, treatment, and management of complications of LAOO.

      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/j.iccl.2017.12.008
       
  • Left Atrial Appendage Occlusion
    • Authors: Ignacio Cruz-Gonzalez; Monica Fuertes-Barahona; Jose C. Moreno-Samos; Rocio Gonzalez-Ferreiro; Yan Yin Lam; Pedro L. Sanchez
      Pages: 253 - 265
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): Ignacio Cruz-Gonzalez, Monica Fuertes-Barahona, Jose C. Moreno-Samos, Rocio Gonzalez-Ferreiro, Yan Yin Lam, Pedro L. Sanchez
      Teaser Since the first percutaneous left atrial appendage occlusion (LAAO), many studies have shown the safety and efficacy of this technique to prevent embolic strokes in nonvavular atrial fibrillation. The design, characteristics, and clinical data of the most frequently used devices for LAAO are reviewed, including the Amplatzer cardiac plug and Amulet (Abbott Vascular), the Watchman (Boston Scientific), and the LARIAT device (SentreHEART). Similarly, newer closer devices, such as Ultraseal (Cardia), LAmbre (Lifetech), and Coherex WaveCrest (Johnson & Johnson), are also discussed. Finally, new technologies still in the stage of preclinical study or in the initial clinical experience are also reviewed.

      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/j.iccl.2017.12.011
       
  • Left Atrial Appendage Occlusion, Shared Decision-Making, and Comprehensive
           Atrial Fibrillation Management
    • Authors: Michael H. Hoskins; Anshul M. Patel; David B. DeLurgio
      Pages: 267 - 283
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): Michael H. Hoskins, Anshul M. Patel, David B. DeLurgio
      Teaser The epidemic of atrial fibrillation (AF) requires a comprehensive management strategy that uses the full force of available data and technology, including anticoagulation, ablative therapy, and left atrial appendage occlusion. Patient-centered care with an emphasis on shared decision-making is particularly relevant to the authors’ understanding of the complexity of AF and has helped them tailor therapy in this ever-growing patient population.

      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/j.iccl.2017.12.006
       
  • Interventional Cardiology Clinics
    • Authors: Matthew J. Price
      Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2
      Author(s): Matthew J. Price


      PubDate: 2018-03-18T12:09:49Z
      DOI: 10.1016/s2211-7458(17)30129-3
       
  • Left Atrial Appendage Closure
    • Abstract: Publication date: April 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 2


      PubDate: 2018-03-18T12:09:49Z
       
  • Cardiac Computed Tomography for Left Atrial Appendage Occlusion
    • Authors: Kasper Korsholm; Jesper Møller Jensen; Jens Erik Nielsen-Kudsk
      Abstract: Publication date: Available online 1 February 2018
      Source:Interventional Cardiology Clinics
      Author(s): Kasper Korsholm, Jesper Møller Jensen, Jens Erik Nielsen-Kudsk
      Teaser Transcatheter left atrial appendage occlusion is increasingly used for stroke prevention in atrial fibrillation. The technique has proven effective and safe in randomized trials and multiple observational studies. The procedure is challenging due to the complex anatomy of the left atrial appendage; accurate cardiac imaging is essential for procedural guidance. Transesophageal echocardiography is the gold standard, but cardiac computed tomography (CT) has gained increasing interest within recent years. Cardiac CT offers high-resolution imaging allowing for preprocedural anatomic evaluation and device sizing, but may also be useful for exclusion of left atrial appendage thrombus, and follow-up assessment of residual peri-device leaks.

      PubDate: 2018-02-03T12:22:32Z
      DOI: 10.1016/j.iccl.2017.12.004
       
  • Interventional Cardiology Clinics
    • Authors: Matthew J. Price
      Abstract: Publication date: January 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 1
      Author(s): Matthew J. Price


      PubDate: 2017-11-17T17:10:47Z
      DOI: 10.1016/s2211-7458(17)30129-3
       
  • Interventional Imaging of the Tricuspid Valve
    • Authors: Francesco Ancona; Eustachio Agricola; Stefano Stella; Cristina Capogrosso; Claudia Marini; Alberto Margonato; Rebecca T. Hahn
      Pages: 13 - 29
      Abstract: Publication date: January 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 1
      Author(s): Francesco Ancona, Eustachio Agricola, Stefano Stella, Cristina Capogrosso, Claudia Marini, Alberto Margonato, Rebecca T. Hahn
      Teaser Nowadays, reasonable transcatheter tricuspid valve (TV) interventions are emerging as therapeutic options for functional tricuspid regurgitation (TR). The preprocedural planning is based on a multimodality imaging approach, which aims to (1) define the mechanisms of TR, (2) characterize TV morphology, (3) analyze the anatomic relationship between the TV apparatus and other structures, and (4) determine the size of the tricuspid annulus and vena cavae. Intraprocedural guidance is based mainly on transesophageal echocardiography (seldom transthoracic) and fluoroscopy, with the recent introduction of fusion imaging.

      PubDate: 2017-11-17T17:10:47Z
      DOI: 10.1016/j.iccl.2017.08.010
       
  • The FORMA Repair System
    • Authors: Rishi Puri; Josep Rodés-Cabau
      Pages: 47 - 55
      Abstract: Publication date: January 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 1
      Author(s): Rishi Puri, Josep Rodés-Cabau
      Teaser Significant tricuspid valve disease affects many patients with left-sided heart disease. Concomitant tricuspid valve surgery for at least moderate tricuspid insufficiency is undertaken far less frequently at the time of left-sided heart surgery. The burden of residual tricuspid disease in high-surgical-risk patients has spawned the evolution of several percutaneous treatment options. A dedicated percutaneously delivered tricuspid Spacer device (FORMA Repair System) has been developed and trialed in humans. This system anchors a Spacer to reduce the regurgitant orifice area, thereby providing a surface for valve leaflet coaptation. This article provides an overview of the FORMA Repair System to date.

      PubDate: 2017-11-17T17:10:47Z
      DOI: 10.1016/j.iccl.2017.08.007
       
  • Systemic Thrombolysis for Pulmonary Embolism
    • Authors: Hafeez Ul Hassan Virk; Sanjay Chatterjee; Partha Sardar; Chirag Bavishi; Jay Giri; Saurav Chatterjee
      Pages: 71 - 80
      Abstract: Publication date: January 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 1
      Author(s): Hafeez Ul Hassan Virk, Sanjay Chatterjee, Partha Sardar, Chirag Bavishi, Jay Giri, Saurav Chatterjee
      Teaser Acute pulmonary embolism presents a clinical challenge for optimal risk stratification. Although associated with significant morbidity and mortality at the population level, the spectrum of presentation in an individual patient varies from mild symptoms to cardiac arrest. Treatment options include anticoagulation, systemic thrombolysis, catheter-based interventions, and surgical embolectomy. In this article, an attempt is made to optimally identify patients who, based on available evidence, may benefit from systemic thrombolytic therapy. The clinical efficacy of systemic thrombolysis must be balanced against increased risks of major bleeding and intracranial hemorrhage.

      PubDate: 2017-11-17T17:10:47Z
      DOI: 10.1016/j.iccl.2017.08.001
       
  • Catheter-Based Embolectomy for Acute Pulmonary Embolism
    • Authors: Wissam A. Jaber; Michael C. McDaniel
      Pages: 91 - 101
      Abstract: Publication date: January 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 1
      Author(s): Wissam A. Jaber, Michael C. McDaniel
      Teaser A significant number of patients with high-risk pulmonary embolism have contraindications to thrombolytic therapy. Catheter-based therapy may be helpful and consists of a multitude of catheters and techniques, some old and some new. Although there are few data supporting the use of any of these techniques, there has been a recent rise in interest and use of catheter-based pulmonary embolectomy. This text describes the contemporary devices used in pulmonary embolism treatment, discusses their challenges, and proposes some future directions.

      PubDate: 2017-11-17T17:10:47Z
      DOI: 10.1016/j.iccl.2017.08.003
       
  • Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary
           Hypertension
    • Authors: Ehtisham Mahmud; Omid Behnamfar; Lawrence Ang; Mitul P. Patel; David Poch; Nick H. Kim
      Pages: 103 - 117
      Abstract: Publication date: January 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 1
      Author(s): Ehtisham Mahmud, Omid Behnamfar, Lawrence Ang, Mitul P. Patel, David Poch, Nick H. Kim
      Teaser Chronic thromboembolic pulmonary hypertension (CTEPH) is associated with several risk factors but is most frequently seen as a rare consequence of an acute pulmonary embolism. Surgical pulmonary thromboendarterectomy (PTE) is potentially curative for CTEPH with the best outcomes seen for the treatment of primarily proximal, accessible lobar or segmental disease. For surgically inoperable patients, percutaneous balloon pulmonary angioplasty (BPA) is feasible and has good short- to mid-term efficacy outcomes. This review focuses on the technique and outcomes associated with BPA which has emerged as a new therapeutic option for CTEPH.

      PubDate: 2017-11-17T17:10:47Z
      DOI: 10.1016/j.iccl.2017.09.003
       
  • Mechanical Circulatory Support for High-Risk Pulmonary Embolism
    • Authors: Mahir Elder; Nimrod Blank; Adi Shemesh; Mohit Pahuja; Amir Kaki; Tamam Mohamad; Theodore Schreiber; Jay Giri
      Pages: 119 - 128
      Abstract: Publication date: January 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 1
      Author(s): Mahir Elder, Nimrod Blank, Adi Shemesh, Mohit Pahuja, Amir Kaki, Tamam Mohamad, Theodore Schreiber, Jay Giri
      Teaser Temporary mechanical circulatory support (MCS) devices have a role in treating high-risk patients with pulmonary embolism with cardiogenic shock. Mechanical circulatory device selection should be made based on center experience and device-specific features. All current devices are effective in decreasing right arterial pressure and providing circulatory support of 4 to 5 L/min. The pulmonary artery pulsatility index may prove to be an unreliable method to assess right ventricular function. Careful clinical evaluation on an individual patient basis should determine the need for MCS.

      PubDate: 2017-11-17T17:10:47Z
      DOI: 10.1016/j.iccl.2017.09.002
       
  • Inferior Vena Cava Filters
    • Authors: John Andrew Kaufman
      Pages: 129 - 135
      Abstract: Publication date: January 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 1
      Author(s): John Andrew Kaufman
      Teaser The inferior vena cava filter clinical environment is notable for the degree of controversy, uncertainty, and fear associated with these devices by both physicians and the public. This article reviews some of the more important current issues with these devices as well as emerging and future trends.

      PubDate: 2017-11-17T17:10:47Z
      DOI: 10.1016/j.iccl.2017.08.004
       
  • Transcatheter Closure of Patent Foramen Ovale
    • Authors: Matthew J. Price
      Abstract: Publication date: October 2017
      Source:Interventional Cardiology Clinics, Volume 6, Issue 4
      Author(s): Matthew J. Price


      PubDate: 2017-09-11T23:42:11Z
      DOI: 10.1016/j.iccl.2017.07.001
       
  • Imaging Assessment of the Interatrial Septum for Transcatheter Atrial
           Septal Defect and Patent Foramen Ovale Closure
    • Authors: Mary Z. Bechis; David S. Rubenson; Matthew J. Price
      Pages: 505 - 524
      Abstract: Publication date: October 2017
      Source:Interventional Cardiology Clinics, Volume 6, Issue 4
      Author(s): Mary Z. Bechis, David S. Rubenson, Matthew J. Price
      Teaser Transcatheter closure of atrial septal defects and patent foramen ovale has become increasingly common with advances in device and imaging technology. The percutaneous approach is now the preferred method of closure when anatomically suitable. Two-dimensional and 3-dimensional echocardiography determines anatomic suitability by characterizing the interatrial defect and its surrounding structures, and is critical for intraprocedural guidance and postprocedure follow-up. This article provides an overview of interatrial anatomy as it pertains to interventional considerations and discusses the transthoracic, transesophageal, and intracardiac echocardiographic modalities used for periprocedural and intraprocedural imaging of the interatrial septum.

      PubDate: 2017-09-11T23:42:11Z
      DOI: 10.1016/j.iccl.2017.05.004
       
  • Current Dataset for Patent Foramen Ovale Closure in Cryptogenic Stroke
    • Authors: Olufunso W. Odunukan; Matthew J. Price
      Pages: 525 - 538
      Abstract: Publication date: October 2017
      Source:Interventional Cardiology Clinics, Volume 6, Issue 4
      Author(s): Olufunso W. Odunukan, Matthew J. Price
      Teaser Approximately one-third of all strokes have no apparent cause. A patent foramen ovale (PFO) is present in as many as 60% of these patients with cryptogenic strokes, which is significantly more frequent than that of the general population. The presumed biologic mechanisms of ischemic stroke in the setting of a PFO are paradoxic embolism from the peripheral venous system through this interatrial shunt or embolism from in situ thrombosis. In this review, the authors summarize and critically assess the contemporary studies evaluating the efficacy and safety of PFO closure for prevention of recurrent cryptogenic strokes.

      PubDate: 2017-09-11T23:42:11Z
      DOI: 10.1016/j.iccl.2017.05.007
       
  • Patent Foramen Ovale and Migraine Headache
    • Authors: David Hildick-Smith; Timothy M. Williams
      Pages: 539 - 545
      Abstract: Publication date: October 2017
      Source:Interventional Cardiology Clinics, Volume 6, Issue 4
      Author(s): David Hildick-Smith, Timothy M. Williams
      Teaser Migraine headache is a common and debilitating disease that has a demonstrable association with the presence of patent foramen ovale (PFO) in multiple case series. Closure of PFO has been performed to try to treat migraine with aura, with variable results. Although early trials suggested benefit to PFO closure, these were of poor quality, and subsequent randomized trials have failed to yield positive results. This article discusses the evidence of an association with PFO and migraine headache, and the trials that have so far been performed to assess the benefits of closure.

      PubDate: 2017-09-11T23:42:11Z
      DOI: 10.1016/j.iccl.2017.05.006
       
  • Interventional Cardiology Clinics
    • Authors: Matthew J. Price
      Abstract: Publication date: October 2017
      Source:Interventional Cardiology Clinics, Volume 6, Issue 4
      Author(s): Matthew J. Price


      PubDate: 2017-09-11T23:42:11Z
      DOI: 10.1016/s2211-7458(17)30011-1
       
  • Transcatheter Tricuspid Valve Intervention/Interventional Therapy FOR
           Pulmonary Embolism
    • Abstract: Publication date: January 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 1


      PubDate: 2017-11-17T17:10:47Z
       
  • The Evolving State of Care for Acute Pulmonary Embolism
    • Authors: Jay Giri
      Abstract: Publication date: January 2018
      Source:Interventional Cardiology Clinics, Volume 7, Issue 1
      Author(s): Jay Giri


      PubDate: 2017-11-17T17:10:47Z
       
  • Tricuspid Clip
    • Authors: Gilbert H.L. Tang
      Abstract: Publication date: Available online 6 November 2017
      Source:Interventional Cardiology Clinics
      Author(s): Gilbert H.L. Tang
      Teaser Symptomatic severe tricuspid regurgitation (TR), if untreated, carries a dismal prognosis. These patients are at very high risk for surgical repair or replacement and transcatheter options to treat TR are emerging. More than 300 transcatheter tricuspid repairs with the MitraClip system have been performed worldwide with promising results. The TriClip system, with the MitraClip NT delivered via a dedicated tricuspid steerable guide catheter, is currently under investigation. This article describes the step-by-step technique on using the MitraClip system to perform transcatheter tricuspid repair using echocardiographic and fluoroscopic guidance. The latest data on worldwide experience with tricuspid clipping are also discussed.

      PubDate: 2017-11-10T13:53:03Z
      DOI: 10.1016/j.iccl.2017.09.001
       
  • Transcatheter Tricuspid Valve Intervention: Addressing an Unmet Clinical
           Need
    • Authors: Azeem Latib
      Abstract: Publication date: Available online 27 October 2017
      Source:Interventional Cardiology Clinics
      Author(s): Azeem Latib


      PubDate: 2017-10-28T08:56:39Z
      DOI: 10.1016/j.iccl.2017.10.001
       
  • Transcatheter Tricuspid Valve Replacement
    • Authors: Amar Krishnaswamy; Jose Navia; Samir R. Kapadia
      Abstract: Publication date: Available online 23 October 2017
      Source:Interventional Cardiology Clinics
      Author(s): Amar Krishnaswamy, Jose Navia, Samir R. Kapadia
      Teaser Tricuspid regurgitation (TR) is a common entity, most commonly functional in nature due to right-sided dysfunction in the setting of concomitant cardiac disease or pulmonary hypertension. Patients living with TR often experience numerous limitations as a result of right-sided heart failure symptoms, including functional decline, frequent hospitalizations, liver failure, and kidney failure. Furthermore, patients with significant TR demonstrate worse survival, although a cause-and-effect relationship has not been proven. For patients with a degenerated surgical bioprosthesis or valve ring, placement of a transcatheter aortic valve prosthesis in a valve-in-valve or valve-in-ring fashion may provide symptomatic benefit. For patients with native valve regurgitation, novel devices for treatment are currently under development.

      PubDate: 2017-10-28T08:56:39Z
      DOI: 10.1016/j.iccl.2017.08.009
       
  • Anatomy of the Tricuspid Valve, Pathophysiology of Functional Tricuspid
           Regurgitation, and Implications for Percutaneous Therapies
    • Authors: Nicola Buzzatti; Michele De Bonis; Neil Moat
      Abstract: Publication date: Available online 21 October 2017
      Source:Interventional Cardiology Clinics
      Author(s): Nicola Buzzatti, Michele De Bonis, Neil Moat
      Teaser The tricuspid valve is a complex dynamic apparatus made up of many different closely linked structures: the annulus, the three leaflets, the chordae, the papillary muscles and the right ventricle. Other nearby structures, such as the coronary sinus ostium, the conduction system, the membranous septum, and the right coronary artery must be taken into account when dealing with the tricuspid. Annulus dilation and leaflet tethering due to right ventricular remodeling are the 2 major mechanisms responsible for most tricuspid regurgitation cases. Precise knowledge of tricuspid anatomy and function, as well as careful preoperative planning, is fundamental for successful transcatheter tricuspid procedures.

      PubDate: 2017-10-28T08:56:39Z
      DOI: 10.1016/j.iccl.2017.08.005
       
  • Percutaneous Tricuspid Annuloplasty
    • Authors: Antonio Mangieri; Scott Lim; Jason H. Rogers; Azeem Latib
      Abstract: Publication date: Available online 19 October 2017
      Source:Interventional Cardiology Clinics
      Author(s): Antonio Mangieri, Scott Lim, Jason H. Rogers, Azeem Latib
      Teaser The tricuspid valve was ignored for a long time. The prevalence of severe tricuspid regurgitation is not negligible, however, and is associated with poor prognosis. In cases of primary tricuspid regurgitation, surgical options are limited by a high risk of mortality and morbidity. New percutaneous approaches are becoming available to meet this consistent unmet clinical need. This review presents the current available devices that reproduce both the complete and uncomplete surgical annuloplasty techniques.

      PubDate: 2017-10-21T08:07:10Z
      DOI: 10.1016/j.iccl.2017.08.006
       
  • Catheter-Directed Therapy for Pulmonary Embolism
    • Authors: Bedros Taslakian; Akhilesh K. Sista
      Abstract: Publication date: Available online 12 October 2017
      Source:Interventional Cardiology Clinics
      Author(s): Bedros Taslakian, Akhilesh K. Sista
      Teaser Acute pulmonary embolism (PE) is the third most common cause of death among hospitalized patients. Treatment escalation beyond anticoagulation therapy is necessary in patients with cardiogenic shock and may be of benefit in select normotensive patients with right heart strain. Percutaneous catheter-based techniques (catheter-directed mechanical thrombectomy, clot maceration, and/or pharmacologic thrombolysis) as an alternative or adjunct to systemic thrombolysis can rapidly debulk central clot in patients with shock. Catheter-directed thrombolysis, which uses a low-dose intraclot prolonged thrombolytic infusion, is a promising but insufficiently studied therapy for patients presenting with acute intermediate-risk PE.

      PubDate: 2017-10-14T07:34:49Z
      DOI: 10.1016/j.iccl.2017.08.002
       
  • Caval Valve Implantation
    • Authors: Alexander Lauten; Henryk Dreger; Michael Laule; Karl Stangl; Hans R. Figulla
      Abstract: Publication date: Available online 12 October 2017
      Source:Interventional Cardiology Clinics
      Author(s): Alexander Lauten, Henryk Dreger, Michael Laule, Karl Stangl, Hans R. Figulla
      Teaser Recently, transcatheter therapy has expanded the treatment options for patients with heart valve disease. With the growing understanding of tricuspid regurgitation and its natural history, it becomes increasingly obvious that this patient population is a heterogeneous cohort presenting for treatment in different stages of a continuous disease process. It is still unclear which interventional approach will result in functional and clinical success and in which subtype of patient population. This article reviews the pathophysiologic background and current evidence for caval valve implantation and examines the potential role of this approach for the treatment of severe tricuspid regurgitation.

      PubDate: 2017-10-14T07:34:49Z
      DOI: 10.1016/j.iccl.2017.08.008
       
  • Forthcoming Issues
    • Abstract: Publication date: October 2017
      Source:Interventional Cardiology Clinics, Volume 6, Issue 4


      PubDate: 2017-09-11T23:42:11Z
       
  • Cryptogenic Stroke and Patent Foramen Ovale Risk Assessment
    • Authors: Emiliya Melkumova; David E. Thaler
      Abstract: Publication date: Available online 29 June 2017
      Source:Interventional Cardiology Clinics
      Author(s): Emiliya Melkumova, David E. Thaler
      Teaser Stroke is a devastating condition. It is the fifth leading cause of death in the United States, and a leading cause of serious long-term disability. Stroke occurs at any age. Younger patients tend to have strokes of undetermined cause, termed cryptogenic. Herein, the authors describe the classification of stroke cause; the risk of recurrent cryptogenic stroke with patent foramen ovale (PFO); a risk assessment model to stratify incidental versus a pathogenic PFO in patients presenting with stroke; and patient selection for device occluder therapy in the context of the long-term follow-up of the RESPECT randomized clinical trial.

      PubDate: 2017-07-04T20:19:36Z
      DOI: 10.1016/j.iccl.2017.05.005
       
  • Identification and Quantification of Patent Foramen Ovale–Mediated
           Shunts
    • Authors: Ahmed N. Mahmoud; Islam Y. Elgendy; Nayan Agarwal; Jonathan M. Tobis; Mohammad Khalid Mojadidi
      Abstract: Publication date: Available online 27 June 2017
      Source:Interventional Cardiology Clinics
      Author(s): Ahmed N. Mahmoud, Islam Y. Elgendy, Nayan Agarwal, Jonathan M. Tobis, Mohammad Khalid Mojadidi
      Teaser Once deemed benign, patent foramen ovale (PFO)–mediated right-to-left shunting has now been linked to stroke, migraine, and hypoxemia. Contrast transesophageal echocardiography is considered the standard technique for identifying a PFO, allowing visualization of the atrial septal anatomy and differentiation from non-PFO right-to-left shunts. Transthoracic echocardiography is the most common method for PFO imaging, being cost-effective, but has the lowest sensitivity. Transcranial Doppler is highly sensitive but is unable to differentiate cardiac from pulmonary shunts; it is the best method to quantitate shunt severity, being more sensitive than transthoracic or transesophageal echocardiography so is our preferred screening method for PFO.

      PubDate: 2017-07-04T20:19:36Z
      DOI: 10.1016/j.iccl.2017.05.002
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.156.37.174
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-